Research Article
Daclatasvir and Sofosbuvir Therapy Enhance Monocyte Phenotypic Changes in Naive Chronic Hepatitis C Patients: A Prospective Cohort Study
Table 4
Comparison of monocyte subsets in CHC patients and healthy controls.
| | | Pre-treatment | Post-treatment | Control | P value |
| | Classical (CD14++ CD16-) | | | | 0.025 | | Mean ±SD | 50.05±18.86 | 47.57±28.17 | 25.4±8.84 | | Median (range) | 52.2(1.82-78) | 58.5(0.26-82) | 25.8(12.6-41) |
| | Classical (CD14++ CD16-) x109/l | | | | 0.0062 | | Mean ±SD | 244±171 | 151±117 | 58±13 | | Median (range) | 193(7-704) | 152(70-379) | 51(27-94) |
| | Intermediate(CD14++CD16+) | | | | 0.0001 | | Mean ±SD | 5.86±3.99 | 2.20±2.23 | 1.39±3.49 | | Median (range) | 5.3(0.11-15) | 1.7(0-8) | 0.37(0.13-5.3) |
| | Intermediate(CD14++CD16+) x109/l | | | | 0.00003 | | Mean ±SD | 28±24 | 6±7 | 2±6 | | Median (range) | 22(0.4-114) | 4(0-22) | 1(0-9) |
| | Non-classical (CD14+CD16++) | | | | 0.0005 | | Mean ±SD | 17.98±7.16 | 7.96±6.64 | 11.33±0.92 | | Median (range) | 16.6(0.12-55) | 6.89(0.01-24.6) | 11.35(4-19) |
| | Non-classical (CD14+CD16++) x109/l | | | | 0.008 | | Mean ±SD | 104±138 | 22±21 | 28±0.2 | | Median (range) | 69(0.7-708) | 19(0-76) | 25(7-56) |
| | CD16+ monocyte | | | | 0.00002 | | Mean ±SD | 24.78±13.25 | 10.17±7.58 | 12.495±4.41 | | Median (range) | 23.1(0.23-58) | 9.8(0.01-28.2) | 13.38(4-19.85) |
| | CD16+ monocyte x109/l | | | | 0.0009 | | Mean ±SD | 132±134 | 29±24 | 30±6 | | Median (range) | 95(0.9-737) | 25(0-92) | 30(7-57) |
| | MFI CD14 | | | | 0.0003 | | Mean ±SD | 29.59±7.06 | 24.44±9.83 | 13.66±1.1 | | Median (range) | 30.25(15.3-45) | 25.5(2-45) | 25.5(7.8-21.2) |
| | MFI CD16 | | | | 0.5315 | | Mean ±SD | 492.43±252.10 | 438.23±282.43 | 371.33±2.83 | | Median (range) | 387(177-1087) | 438(26-1137) | 394(201-556) |
|
|
Significant; MFI: median fluorescent intensity. |
